GSK and Pfizer shares are trading lower amid possible declining Respiratory Syncytial Virus vaccine sales after the CDC recommended a narrow age cohort for routine use.
Portfolio Pulse from Benzinga Newsdesk
GSK and Pfizer shares are trading lower due to potential declining sales of their Respiratory Syncytial Virus (RSV) vaccines. This follows the CDC's recommendation for a narrow age cohort for routine use.
October 10, 2024 | 7:44 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
GSK shares are trading lower due to potential declining sales of its RSV vaccine after the CDC recommended it for a narrow age cohort.
The CDC's recommendation for a narrow age cohort for RSV vaccine use could lead to reduced sales for GSK, negatively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Pfizer shares are trading lower due to potential declining sales of its RSV vaccine after the CDC recommended it for a narrow age cohort.
The CDC's recommendation for a narrow age cohort for RSV vaccine use could lead to reduced sales for Pfizer, negatively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80